Purpose: This is a randomized trial to evaluate the efficacy and safety of a new type of medication in Ulcerative Colitis. The medication (Icotrokinra) is an oral Il-23 pill taken daily. Il-23 medications have shown significant success in treating IBD. In early trials, this drug has shown great efficacy for patients who have Crohn’s Disease and Ulcerative Colitis. The study will last up to 4 years. All costs (study meds, lab work, procedures) are covered by the sponsor. Patients will be compensated for time and travel.
Our staff would be happy to review the details of the study with you.
Qualifications: - ≥18 years of age - Have a confirmed diagnosis of Ulcerative Colitis - Have tried and failed at least 1 prior treatment for your Ulcerative Colitis. - Have not had removal of your colon or a current ostomy or fistula
J and J Iconic Crohn's Disease Study Fundor: Janssen Research & Development, LLC
A clinical research study testing a once-daily oral medication (Icotrokinra) for Crohn’s Disease, with all study-related care provided at no cost.
PIs: Dr. Meena Bewtra, MD, MPH, PhD and Dr. Christopher Schmoyer, MD
Purpose: This is a randomized trial to evaluate the efficacy and safety of a new type of medication in Crohn’s Disease. The medication (Icotrokinra) is an oral Il-23 pill taken daily. Il-23 medications have shown significant success in treating IBD. In early trials, this drug has shown great efficacy for patients who have Crohn’s Disease and Ulcerative Colitis. The study will last up to 4 years. All costs (study meds, lab work, procedures) are covered by the sponsor. Patients will be compensated for time and travel.
Our staff would be happy to review the details of the study with you.
Qualifications: - ≥18 years of age - Have a confirmed diagnosis of Crohn’s Disease - Have tried and failed at least 1 prior treatment for your Crohn’s Disease. - Have not had removal of your colon or a current ostomy